Fulcrum Announces Initiation of Phase 2b Clinical Trial of Losmapimod

CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it has initiated ReDUX4, a Phase 2b clinical trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). The clinical trial is designed to evaluate the efficacy and safety of losmapimod, an investigational selective p38α/β MAPK inhibitor, in addressing the underlying cause of FSHD, a rare, progressive and disabling muscular dystrophy.

See News Release.